|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
3/19/2013 8:39:44 AM
Two Boston-area biotech companies — one working on a treatment for hepatitis C, the other aimed at drugs to treat disease caused by bacterial biothreat pathogens — are set to raise a combined total of $146 million through two initial public offerings during the week starting March 18. According to Renaissance Capital, Enanta Pharmaceuticals Inc. in Watertown, Mass., and Tetraphase Pharmaceuticals Inc. in Cambridge, Mass., will both become public companies during the week. Enanta, which plans to be listed on the Nasdaq exhange under the ticker, “ENTA,” could raise as much as $64 million in its IPO. The price range for its offering of 4 million shares is $14 to $16 per share. In a filing with the Securities and Exchange Commission last November, Enanta said it expected to have $72 million in assets as of the end of 2012. The company has raised a total of $160 million in redeemable convertible preferred stock to date. The company had revenue of $41 million for the full year 2012, and had $21 million in net income.
|
|
|
|
|
|
|
|
|
|
|